1. Home
  2. SQFT vs OGEN Comparison

SQFT vs OGEN Comparison

Compare SQFT & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presidio Property Trust Inc.

SQFT

Presidio Property Trust Inc.

N/A

Current Price

$2.51

Market Cap

3.2M

Sector

Real Estate

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.58

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SQFT
OGEN
Founded
1999
1996
Country
United States
United States
Employees
15
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
2.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
SQFT
OGEN
Price
$2.51
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.0K
39.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.50
52 Week High
$23.00
$1.49

Technical Indicators

Market Signals
Indicator
SQFT
OGEN
Relative Strength Index (RSI) 44.47 44.28
Support Level $2.14 $0.56
Resistance Level $2.57 $0.64
Average True Range (ATR) 0.11 0.03
MACD 0.02 -0.00
Stochastic Oscillator 29.54 30.47

Price Performance

Historical Comparison
SQFT
OGEN

About SQFT Presidio Property Trust Inc.

Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: